Chandrakant Panchal
Director/Board Member at CANADIAN OIL RECOVERY & REMEDIATION ENTERPRISES LTD.
Net worth: 118 558 $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| G. Anthony | M | 68 |
University of Western Ontario
| 13 years |
| Linda J. Sterling | F | 63 | 23 years | |
| Albert Beraldo | M | - | 8 years | |
| Jeffrey Kraws | M | 59 | 11 years | |
| John Lorenzo | M | 80 | 16 years | |
| Yahia A. Gawad | M | 66 | 27 years | |
| Karen Dawes | F | 72 | 5 years | |
| Julian Neil Tabatznik | M | 74 | 21 years | |
| Eamonn Peters | M | - | 1 years | |
| John Sampson | M | - | 3 years | |
| Delphine Davan | F | - | 1 years | |
| Anthony Porcheron | M | 55 | 1 years | |
| David Freeman | M | - | - | |
| Turki Khalid Khoj | M | - | 14 years | |
| Sohail Hameed Khan | M | - | 14 years | |
| Fred di Tomaso | M | - | 14 years | |
| Raymond Stapell | M | - | 16 years | |
| Jack Geltosky | M | 78 | 4 years | |
| Jane E. Pagel | M | - | 6 years | |
| William F. Madison | M | 81 | 17 years | |
| James A. Essex | M | 76 | 25 years | |
| Evelyn Pau | M | - | 1 years | |
| Anton Ayoub | M | - | - | |
| Michael Lavergne | M | - | 6 years | |
| Roland Alvarez | M | - | 6 years | |
| John McVicar | M | - | 3 years | |
| Gordon West | M | 91 |
University of Toronto
| 52 years |
| Eileen McCormack | F | - | 2 years | |
| Stephen Kim | M | - | 2 years | |
| Randy Koroll | M | 59 | 4 years | |
| Minh To | M | - | 1 years | |
| Tsogtgerel Bayanjargal | M | 58 | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Richard la Rue | M | - |
Ambrilia Biopharma, Inc.
 Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada.
Procyon Biopharma, Inc.
 Procyon Biopharma, Inc. Miscellaneous Commercial ServicesCommercial Services Procyon Biopharma, Inc. is a biopharmaceutical company engaged in the discovery and development of innovative cancer therapeutic, screening, and diagnostic products and technologies. Procyon has acquired four technologies of which two are broad platform technologies. These two are Prostate Secretory Protein (PSP94), for the prostate cancer market, and the ANA technology platform, that has been developed to improve the immune system and resistibility of cancer. The company is headquartered in Dorval in Québec, Canada | 2 years |
| Setu Purohit | M | 43 | 7 years | |
| Alexander Gress | M | 50 | - | |
| William G. Chidley | M | - |
University of Western Ontario
University of Toronto
| 9 years |
| T. Jacques Brault | M | - | 6 years | |
| Raf Hofstein | M | 74 |
Toronto Innovation Acceleration Partners
 Toronto Innovation Acceleration Partners BiotechnologyHealth Technology Toronto Innovation operates as a commercialization agent. Its technologies disclosed span therapeutics, medical devices and diagnostic imaging, information and communications technologies, and advanced manufacturing and clean technologies. The company was founded by Raphael Hofstein in June 2009 and is headquartered in Toronto, Canada. | 11 years |
| Cameron Groome | M | - | 4 years | |
| Elizabeth Williams | F | - | 7 years | |
| Philippe Calais | M | 65 |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | 1 years |
| Malvin Spooner | M | - |
University of Western Ontario
University of Toronto
| 6 years |
| Amin I. Khalifa | M | 70 | 6 years | |
| Michael Hibberd | M | 68 |
University of Western Ontario
University of Toronto
| 9 years |
| Timothy Penner | M | 68 |
Toronto Innovation Acceleration Partners
Toronto Innovation Acceleration Partners BiotechnologyHealth Technology Toronto Innovation operates as a commercialization agent. Its technologies disclosed span therapeutics, medical devices and diagnostic imaging, information and communications technologies, and advanced manufacturing and clean technologies. The company was founded by Raphael Hofstein in June 2009 and is headquartered in Toronto, Canada. | - |
| Michael J. Bronskill | M | - |
University of Toronto
| 3 years |
| Anthony Eisenberg | M | 41 | 2 years | |
| Hassan M. Jameel Dahlawi | M | - | 10 years | |
| John B. Watt | M | - |
University of Western Ontario
University of Toronto
| 7 years |
| Edward J. Gress | M | - | - | |
| Edward Nunes-Vaz | M | - |
University of Toronto
| 6 years |
| Alexander D. G. Reid | M | 85 | 15 years | |
| Yong Guan Koh | M | 78 |
University of Toronto
| 6 years |
| Shahraab Ahmad | M | 46 | 3 years | |
| Bruce Levitt | M | - |
University of Western Ontario
| 4 years |
| Benjamin Leavenworth | M | - | 1 years | |
| William N. Gula | M | - |
University of Toronto
| 7 years |
| Brian O’Neill | M | - | 1 years | |
| William Li | M | 61 | 2 years | |
| Janet Giesselman | F | 69 | 2 years | |
| Paul Darby | M | - |
University of Toronto
| 4 years |
| Mario Charles Vachon | M | - |
University of Western Ontario
| 6 years |
| Burt Jordan | M | 56 | 3 years | |
| Andrew L. Strong | M | 57 | 4 years | |
| Hussain Ibrahim Saleh al-Shahristani | M | 82 |
University of Toronto
| 4 years |
| Bhupender Gosain | M | - | - | |
| Kyle Langstaff | M | 40 | 4 years | |
| Muhamad Amza Ali | M | 62 | 4 years | |
| Arash Moghani | M | 39 | 7 years | |
| Paul Dick | M | - | 2 years | |
| Geofrey Myers | M | 73 |
University of Toronto
| 7 years |
| Wayne McKinnon | M | - | - | |
| Tadeusz Witkowicz | M | - |
University of Toronto
| 6 years |
| Eric Salsberg | M | 78 |
University of Toronto
| 7 years |
| Abraham I. Aronowicz | M | - |
University of Toronto
| 5 years |
| Gail Mudie | F | - |
University of Toronto
| 6 years |
| John Duncan Pennal | M | 77 |
University of Toronto
| 7 years |
| David William Childs | M | - |
University of Western Ontario
University of Toronto
| 7 years |
| John A. Honderich | M | 77 |
University of Toronto
| 7 years |
| Donald Sheldon | M | 77 |
University of Toronto
| 6 years |
| Koon Hung Tang | M | 78 |
University of Toronto
| 4 years |
| Jean Fraser | F | 76 |
University of Toronto
| 8 years |
| William John Bennett | M | - |
University of Toronto
| 7 years |
| Michael R. Gardiner | M | - |
University of Toronto
| 7 years |
| John A. Dixon | M | - |
University of Toronto
| 5 years |
| Robert Moses | M | - |
University of Toronto
| 8 years |
| Russell Hiscock | M | 72 |
University of Western Ontario
University of Toronto
| 2 years |
| Michael Richard Faye | M | - |
University of Toronto
| 6 years |
| Rob Cassels | M | 69 |
University of Toronto
University of Western Ontario
| 6 years |
| David P. Carbonaro | M | 64 | - | |
| Bonabes-Olivier de Rougé | M | - |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | 5 years |
| Gary H. Luftspring | M | - |
University of Toronto
| 7 years |
| Don Lato | M | - |
University of Western Ontario
University of Toronto
| 7 years |
| Geoffrey P. Cornish | M | - |
University of Western Ontario
| 7 years |
| Peter Lea | M | - |
University of Toronto
| 23 years |
| William Middleton | M | - |
University of Western Ontario
| 7 years |
| Seong Lim Gooi | M | 76 |
University of Toronto
| 6 years |
| Seong Heen Gooi | M | 74 |
University of Toronto
University of Western Ontario
| 7 years |
| Paul Sabourin | M | - |
University of Toronto
University of Western Ontario
| 7 years |
| Tseren Purev | M | 64 | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Canada | 79 | 79.00% |
| Ireland | 6 | 6.00% |
| United States | 5 | 5.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Chandrakant Panchal
- Personal Network
